SNDX Earnings

SNDX reported its earnings on 2026-04-30, showcasing a revenue of 64.86M against an estimate of 70.01M, resulting in a -7.35% surprise. The EPS was -0.48, surpassing the expected -0.58 by 17.24%. The stock experienced a -10.83% price change on the earnings day and a -3.64% change over the next five days, reflecting market reactions to the results.

Following SNDX's earnings announcement on 2026-04-30, the stock price moved by -10.83% on the day of the release. Over the subsequent five days, it saw a -3.64% change. Historically, SNDX's stock price tends to shift by an average of -3.05% in the 10 days leading up to earnings and -0.77% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate SNDX's annual revenue to reach 85.54M, while the EPS is projected at -0.43. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SNDX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SNDX's stock price typically moves by -3.05% in the 10 days before its earnings and -0.77% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.43 and revenue of 85.54M.

Syndax Pharmaceuticals reported a strong financial performance with a 224% year-over-year revenue increase, driven by demand for Revuforj and Niktimvo. The Q&A highlighted positive market dynamics, such as high investigator interest in Niktimvo for IPF and potential market leadership for Revuforj. Despite some uncertainties in guidance, the overall sentiment is positive due to strong revenue growth, promising pipeline developments, and robust financial health, suggesting a positive stock price movement.